Levepsy 750 Tablet contains Levetiracetam 750 mg, an anticonvulsant medication primarily indicated for the treatment of epilepsy. It is utilized as adjunctive therapy for partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in adults and pediatric patients. Levetiracetam’s exact mechanism of action is not fully understood; however, it is believed to modulate synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and seizure propagation. Levepsy 750 Tablet is administered orally and exhibits rapid absorption with high bioavailability, allowing for convenient dosing schedules. It is generally well tolerated, with common adverse effects including somnolence, dizziness, headache, and fatigue. Dose adjustments may be necessary in patients with renal impairment to prevent accumulation and toxicity. Levepsy should be used cautiously in patients with a history of psychiatric disorders or suicidal ideation, as mood changes have been reported. Regular monitoring and adherence to prescribed dosing are essential to optimize therapeutic outcomes and minimize adverse events. Levepsy 750 Tablet should be prescribed and used under the supervision of a qualified healthcare professional, with consideration of individual patient factors and concomitant medications.